Interview 29 May 2017 Meet the Founder of the UK’s Best Biotech that Discovered Humira …Antibody Technology (CAT), would go on to be the biggest success story in UK biotech after it discovered the blockbuster therapeutic antibody, Humira, and became part of AstraZeneca in 2006… May 29, 2017 - 9 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
Sponsored by KBI Biopharma 17 Sep 2024 ADCs that deliver: The secret lies in rigorous characterization Antibody-drug conjugates (ADCs) represent an innovative class of potent anti-cancer agents. They combine the specificity of a monoclonal antibody with the potency of a cytotoxic drug, enabling targeted killing of… September 17, 2024 - 7 minutesmins - By Ute Boronowsky Share WhatsApp Twitter Linkedin Email
News and Trends 20 Nov 2023 M&As: what’s up with the ADC buying spree? Antibody drug conjugates (ADCs) have been much sought-after through investments of late, with big pharma eyeing these drugs developed by various biotechs, to eventually nab them. With yet another ADC… November 20, 2023 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 1 Dec 2016 Spain joins the Antibody-Drug Conjugate Bandwagon to fight Cancer …antibody-drug conjugate (ADC) candidate, MI130110, against fibrosarcoma and multiple myeloma. Which means the popular ADC field has managed to attract yet another company into what could be a major breakthrough… December 1, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 18 Nov 2022 Sanofi’s Enjaymo for hemolytic anemia given marketing authorization by EC …the only approved treatment for CAD and is a first-in-class humanized monoclonal antibody that is designed to selectively target and inhibit the classical complement pathway specific serine protease, C1s. It… November 18, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 11 Aug 2020 How European Startups Have Advanced Cancer T-Cell Therapy in 2020 …tweak existing human TCRs in their cell therapies, T-knife sources its cancer-hunting TCRs from mice. The firm genetically modifies mice to produce fully humanized TCRs and injects them with human… August 11, 2020 - 8 minutesmins - By Kostas Vavitsas Share WhatsApp Twitter Linkedin Email
Best in Biotech 8 Jun 2023 Six companies that have made their name in the cardiovascular space …glenzocimab, is a humanized monoclonal antibody fragment. It is directed against the human platelet glycoprotein GPVI, as GPVI blockade has been seen to demonstrate its effective antithrombotic potential in experimental… June 8, 2023 - 7 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 31 Jan 2023 BiVictriX announces positive data from leukemia study …the only approved antibody drug conjugate (ADC) indicated for the treatment of acute myeloid leukemia (AML). One of the significant toxicities of GO is the reduction in normal neutrophil counts… January 31, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 14 Sep 2022 Tumors destroyed in five types of cancer by cell therapy from LIfT BioSciences …positive results using a special type of partially humanized mouse model to enable N-LIfT to work in mice. However, the company say it’s official position is that mouse models are… September 14, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jun 2017 Novartis Tops Ophthalmology Blockbuster Eylea in Phase III Trials …humanized single chain antibody fragment that is much smaller (26kDa) than its competitors, allowing for better tissue penetration and more rapid clearance from the systemic circulation. The drug was moved… June 20, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
In Depth 19 Jan 2024 Re-coding the brain: Is CRISPR capable of curing neurodegenerative diseases? …Alzheimer’s patient, as well as in humanized mouse models. Furthermore, the approach did not affect the levels of other APOE variants believed to have a neutral or protective effect. Of… January 19, 2024 - 9 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 11 Oct 2022 Muna Therapeutics gets $4.9M grant for Parkinson’s disease research …the mechanism of Kv1.3 in microglial activation and the role of Kv1.3 blockade, in vitro in human cells and in vivo in humanized mouse models, to achieve the normalization of… October 11, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email